Premium
Dasatinib treatment for Philadelphia chromosome‐positive leukemias
Author(s) -
Khoury Hanna Jean,
Guilhot François,
Hughes Timothy P.,
Kim DongWook,
Cortes Jorge E.
Publication year - 2009
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.24155
Subject(s) - dasatinib , medicine , philadelphia chromosome , oncology , chromosome , genetics , cancer research , chromosomal translocation , imatinib , myeloid leukemia , gene , biology
Dasatinib is a highly potent Bcr‐Abl inhibitor that is approved for the treatment of imatinib‐resistant or ‐intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome‐positive acute lymphoblastic leukemia. Across a series of phase 2 and 3 trials, dasatinib was associated with durable treatment responses in all phases of the disease and was well tolerated. For this article, the authors reviewed available information on specific side effects associated with the use of dasatinib. On the basis of more than 2 years' experience of dasatinib treatment during clinical trials, they provide practical recommendations for side‐effect management. Cancer 2009. © 2009 American Cancer Society.